Search clinical trials for: Anti-neutrophil cytoplasmic antibody

Total 5264 results

Regeneron Pharmaceuticals

Recruiting

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma (OLYMPIA-4)

B-Cell Non-Hodgkin Lymphoma (B-NHL)

Taiwan, Spain, Korea, Republic of, Thailand, Australia, Italy, Malaysia, Turkey
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer

Breast Cancer | Triple Negative Breast Cancer
Shandong New Time Pharmaceutical Co., LTD
Sun Yat-sen University

Not yet recruiting

Phase I Study of LNF1901 in Advanced Malignant Tumors

Advanced Malignant Tumors
Hangzhou DAC Biotechnology Co., Ltd.

Not yet recruiting

A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies

Advanced Solid Tumors | Hematological Malignancies
Laura Huppert, MD, BA
Ambrx, Inc.

Not yet recruiting

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

Triple Negative Breast Cancer | Hormone Receptor Positive Breast Carcinoma | HER2 Low Breast Carcinoma | Hormone-receptor-positive Breast Cancer

United States
Huabo Biopharm Co., Ltd.

Recruiting

A Study of HB0025 Injection in Patients With Advanced Renal Cancer

Renal Cancer

China
Radboud University Medical Center
Pfizer; ImaginAb, Inc.; University Hospital Tuebingen

Not yet recruiting

Immuno-pet iMaging resPonses administeRed Immune checkpoiNt inhibiTor (IMPRINT)

NSCLC

Germany, Netherlands
Pfizer
Bristol-Myers Squibb

Recruiting

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

Multiple Myeloma

United States, Canada
Xijing Hospital
Beijing GD Initiative Cell Therapy Technology Co., Ltd.

Not yet recruiting

Allogeneic Gammadelta T Cells Combined With Interferon-α1b or PD-1 Monoclonal Antibody in Stage III-IV Amenable to Surgical Resection Melanoma

Melanoma
Janssen Research & Development, LLC

Recruiting

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (MonumenTAL-6)

Relapsed or Refractory Multiple Myeloma

Germany, Korea, Republic of, Italy, France, Japan, Israel, Belgium, Australia, Denmark, Sweden, Brazil, China, Spain, Czechia, Turkey, Poland, Netherlands, Argentina, Canada, United Kingdom, Greece, India
Nathan Denlinger
Bristol-Myers Squibb

Recruiting

CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma

B-Cell Non-Hodgkin Lymphoma-Recurrent | Diffuse Large B-Cell Lymphoma-Recurrent | Follicular Lymphoma-Recurrent | High Grade B-Cell Lymphoma-Recurrent | Primary Mediastinal Large B-Cell Lymphoma-Recurrent | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent and other conditions

United States
Chinese PLA General Hospital

Recruiting

PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC

Colorectal Neoplasms | Colorectal Cancer | Microsatellite Stable Colorectal Carcinoma | RAS Mutation

China
University of California, San Diego
National Cancer Institute (NCI); University of California, Los Angeles

Recruiting

Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer

Pancreatic Cancer

United States
Sun Yat-sen University
Wuzhou Red Cross Hospital; Zhongshan People's Hospital, Guangdong, China

Recruiting

Epstein-Barr Virus and Cancer Risks (EBVCR)

Cancer

China
Chinese PLA General Hospital

Recruiting

Microecology and Immunity in Patients With Anti-MDA5 Antibody Positive Dermatomyositis and Interstitial Lung Disease

Microbiome | Immune Function | Anti-MDA5 Antibody Positive Dermatomyositis

China
National Cancer Institute (NCI)

Recruiting

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditions

United States
Harbin Medical University

Not yet recruiting

A Study of Cadonilimab Combined With AK112 as Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Xiamen University
Xiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise...

Not yet recruiting

Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women

Cervical Cancer | Condylomata Acuminata

China
Sinocelltech Ltd.

Not yet recruiting

Efficacy and Safety of SCT650C in Participants With Axial Spondyloarthritis

Axial Spondyloarthritis

Turkey
Ze-yang Ding, MD
Geneplus-Beijing Co. Ltd.; Chinese Cooperative Group of Liver Cancer (CCGLC)

Recruiting

DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma (CCGLC-009)

Cholangiocarcinoma Non-resectable

China
Fudan University
Shanxi Province Cancer Hospital; Inner Mongolia Cancer Hospital Affiliated...

Recruiting

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Advanced Thyroid Cancer Patients Who Received Target Therapy

China
Navy General Hospital, Beijing

Recruiting

Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma

Refractory Classic Hodgkin Lymphoma | Relapsed Classic Hodgkin Lymphoma

China
Memorial Sloan Kettering Cancer Center
Genentech, Inc.

Recruiting

A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma

Mantle Cell Lymphoma | MCL

United States
Best Healthcare Inc.

Not yet recruiting

Persistence of Hepatitis A Antibody in Healthy Adults ~32 Years Post Vaccination.

Hepatitis A
Fundacion Clinic per a la Recerca Biomedica
Hospital Sant Joan de Deu

Recruiting

Antibody-mediated NMDA Receptor Encephalitis: Symptoms, Biomarkers, and Mechanisms of the Prolonged Recovery Stage (AMENDS)

Anti-NMDA Receptor Encephalitis

Spain
IMBiologics Corp.

Not yet recruiting

A Study of IMB-101 in Healthy Volunteers and Participants With Rheumatoid Arthritis

Rheumatoid Arthritis
University of Kansas Medical Center
National Cancer Institute (NCI)

Recruiting

Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Metastatic Cholangiocarcinoma | Locally Advanced Cholangiocarcinoma | Stage III Hilar Cholangiocarcinoma AJCC v8 | Stage IV Hilar Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Recurrent Cholangiocarcinoma

United States
Ruijin Hospital

Recruiting

Safety and Efficacy of LPE in Clearing DSA in Patients Who Received Allo-HSCT

Leukemia

China
FutureGen Biopharmaceutical (Beijing) Co., Ltd

Recruiting

M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

Locally Advanced Unresectable or Metastatic Gastric Cancer | Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

China
Providence Health & Services

Recruiting

Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

Primary Central Nervous System Lymphoma

United States
Boston University
Takeda

Recruiting

Respiratory Microbiota and Immune Response in CVID

CVID

United States
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Recruiting

Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis

Dermatitis, Atopic

China
National Cancer Institute (NCI)

Recruiting

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Neuroblastoma | Ganglioneuroblastoma, Nodular

United States
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Not yet recruiting

A Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout

Acute Gout
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)

Hodgkin Lymphoma

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC

Head and Neck Squamous Cell Carcinoma

China
Peking Union Medical College Hospital

Recruiting

COVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker Research

Lung Cancer | Chemotherapy | Antibody | COVID-19 Recurrent | Vaccination | Immune Checkpoint Inhibitor

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia | Treatment

China
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Not yet recruiting

Retifanlimab With Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma

Recurrent Glioblastoma | Recurrent WHO Grade 4 Glioma

United States
Fudan University

Recruiting

PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy

Nasopharyngeal Carcinoma

China
IRCCS National Neurological Institute "C. Mondino...

Recruiting

HD-EEG Connectivity Changes in Migraine Patients Undergoing Treatment With Anti-CGRP mAbs

Migraine Disorders | Chronic Migraine | Episodic Migraine

Italy
Pfizer

Recruiting

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Multiple Myeloma

United States, Japan, Finland, Norway, Spain, Sweden, Canada, Belgium, Italy, France, Germany, Brazil, Argentina, Czechia
Centre Leon Berard
NETRIS Pharma

Recruiting

Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX] (AML-NET)

Acute Myeloid Leukemia Refractory

France
Astellas Gene Therapies

Recruiting

A Study About Antibody Levels and Biomarkers in the Blood in People With Late-onset Pompe Disease

Pompe Disease (Late-onset)

United States, Spain, France, Taiwan, Italy, Australia
National Cancer Institute (NCI)

Recruiting

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

Metastatic Colorectal Cancer

United States
Fusion Pharmaceuticals Inc.
AstraZeneca

Recruiting

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

Advanced Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Pancreatic Ductal Adenocarcinoma | Metastatic Colorectal Carcinoma

United States, Canada
Cantargia AB

Recruiting

A Study to Investigate the Safety and Tolerability of CAN10 Antibody in Healthy Subjects and in Subjects With Plaque Psoriasis.

Healthy | Plaque Psoriasis

Germany
Bio-Thera Solutions

Recruiting

Assessment of Safety, Tolerability and Pharmacokinetics With BAT4706 and BAT1308 in Advanced Solid Tumors Patients

Advanced Solid Tumor

China
Asan Medical Center
Chonnam National University Hospital; Ulsan University Hospital; Seoul National... and other collaborators

Recruiting

Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma

Hepatocellular Carcinoma

Korea, Republic of
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.

Locally Advanced Unresectable Esophageal Squamous Carcinoma

China

Search clinical trials for: Anti-neutrophil cytoplasmic antibody

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations